Peptide Empire has expansion plans

Semaglutide reaches the kidney trial

The kidney paper is where the scale of the ambition becomes clear. In FLOW, a trial of 3,533 people with type 2 diabetes and chronic kidney disease, semaglutide reduced a combined outcome that included kidney failure, at least a 50% fall in estimated kidney filtration, or death from kidney or cardiovascular causes. A drug associated with appetite and blood sugar had been tested against the course of a serious organ disease.

Those kidney findings earn my respect. FLOW concerned people with diabetes and established kidney disease. Extending the result to a healthy person’s future kidneys would require a different trial.

Peptide Empire takes its name from this restless accumulation of ambitions. Weight, immunity, growth, sex, aging: the territory gets larger very quickly. Some of the expansion has substantial trials behind it. Elsewhere a hormone reading or an account of better sleep is doing an extraordinary amount of work.

Appetite trials and a weight-loss comparison

Semaglutide is an especially useful place to begin because several of its ambitions were tested separately. STEP 1 measured weight change in adults with overweight or obesity without diabetes. SELECT followed people with established cardiovascular disease and overweight or obesity, also without diabetes. FLOW addressed a different population again. The programme becomes more impressive as those distinctions become visible.

It also becomes less tidy. A direct weight-loss comparison favoured tirzepatide over semaglutide. I owe no allegiance to a reigning champion: one drug can lose that comparison while retaining useful findings about other outcomes. The semaglutide essay follows those separate contests, including their side effects.

The other ambitions

Thymosin Alpha-1 has a long immune-research history, but its largest sepsis trial found no statistically significant reduction in deaths at 28 days. The thymosin page starts with the earlier trial and follows the survival question into the larger test.

For CJC-1295, the striking achievement was chemical: a blood-protein attachment prolonged its action. Growth hormone and IGF-1 stayed elevated in healthy adults. Sleep, strength and recovery remain much larger claims than that result can carry. CJC-1295 and its albumin attachment gets into the distinction between DAC and no-DAC.

PT-141 reached a defined prescription use as bremelanotide. Its phase 3 trials measured desire and the distress associated with low desire; the PT-141 page gives those outcomes room of their own.

Then there is NAD+, a coenzyme rather than a peptide. It has acquired neighbouring territory in the longevity discussion. The human evidence for broad benefits remains limited, even though blood levels can rise. NAD+ precursors: NMN, NR follows the narrower muscle and walking findings. NAD+’s walking and muscle findings interest me; rejuvenation is a harder claim to pin down.

A catalogue of the claims

The comparison page puts the ambitions alongside the actual outcomes. The reading list contains the published sources, and about Peptide Empire explains why this field deserves such close attention. A large name leaves plenty of room for modest conclusions.